Abstract：Objective To probe the clinical characteristics of patients with high-risk human papillomavirus of human papilloma virus (HPV)16 infection. Methods A total of 542 patients who were positive for HPV in HPV molecular test were selected from Beijing Jingmei Group General Hospital from January 2013 to December 2021. The patients were analyzed for co-infection with other HPV, infection in different age groups and negative conversion of HPV16. Results Of the 542 patients, 330(60.9%) were single positive, 173(31.9%) were complicated with other high-risk infections, and 39(7.2%) were complicated with low-risk infections The prevalence rate of CIN II and above in cervical biopsy with other high risk group (44.2%) was higher than that in cervical biopsy with low risk group (21.4%),(χ2=4.880, P=0.027) . There was no significant difference in the overall distribution of the three types of infection among the age groups ≤29,30-39,40-49,50-59 and ≥60,(χ2=11.185, P=0.191) . There was no significant difference in the constituent ratio of cervical biopsy between ≤29-year-old group and 30-49-year-old group (χ2=3.369, P=0.338) .The detection rate of CIN III in 30-49 age group was higher than that in other age groups (χ2=4.566, P=0.033), and the detection rate of CIN was higher in under 50 age group (χ2=10.313,P<0.001). Among the 183 follow-up patients, 134 cases turned negative for HPV16, with a median time of 16 months (2-75 months), and 152 cases turned negative for HPV16, with a median time of 1-39 months (1-39 months), the median was 8 months(U=6681,P＜0.0001). Conclusions Clinically, colposcopic biopsy should be performed actively for patients with HPV16 infection who are less than 50 years old and complicated with other high-risk infections.
Bertoli H K,Thomsen L T,Iftner T,et al. Risk of vulvar,vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical humanpapillomaviyus(HPV) status: apopulation based prospective cohort[J].Gynecol Oncol,2020,157(2):456-462.
Olusola P,Banerjee H N,Philley J V,et al. Human papilloma virus-associated cervical cancer and health disparities[J]. Cells,2019,8(6):622-633.
[6]
Chan C K,Aimagambetova G,Ukybassova T,et al. Human papillomavirus infection and cervical cancer: epidemiology screening and vaccination - review of current perspectives[J]. J Oncol,2019,2019: 3257939.
Schiffman M,Doorbar J,Wentzensen N, et al.Carcinogenic human papillomavirus infection[J].Nat Rev Dis Primers,2016,12(1);2:16086.
[10]
Perkins R B, Guido R S,Castle P E,et al.2019 ASCCP risk based management consensus guidelines for abnormal cervical cancer screening tests and cancer precirsors[J].J Low Genit Tract Dis,2020,24(2):102-131.
Fontham E,Wolf A,Church T R,et al.Cervical cancer screeningfor individuals at aver agerisk:2020 guideline update from the American Cancer Society[J].CA Cancer J Clin,2020:Onlineahead of print.
2023, Vol. 34 
